EmergingGrowth.com Reports on Star Scientific, Most Opinions cost More

Fri Jan 11, 2013 8:05am EST

* Reuters is not responsible for the content in this press release.

MIAMI, Florida, January 11, 2013 /PRNewswire/ --

    EmergingGrowth.com, a leading digital financial media company, Reports on Star
Scientific. Discussion also includes Phillip Morris, Altria, Reynolds American, and

    Feature your company on EmergingGrowth.com. Visit EmergingGrowth.com to find out

    Star Scientific (NASDAQ : STSI) has a market cap of $444 million and is involved in
the manufacture, distribution, and sale of consumer products, dietary supplements, and
dissolvable tobacco. The company has a bunch of mega-cap competitors with Philip Morris
(NYSE : PM) (market cap $144bln), Altria (NYSE : MO) ($65bln), Reynolds American (NYSE :
RAI) ($24bln) and Lorillard (NYSE : LO) ($15.26bln). Star Scientific announced a couple
of months back that it was getting out of the smokeless tobacco business and focusing
instead on hawking dietary supplements. The stock dropped to a 52-week low in November
of $1.56, but has seen a significant rise and is currently trading at $2.65 (52-week
range is $1.56 - $5.05). This coincidentally matches the same time when institutional
funds began completing 13F filings. In the latest filing, net institutional purchases
totaled approximately 13 million shares. This represents roughly 9.3% of the company's
current float of 140 million shares. On December 14th the stock had a short Interest of
29.5 million, close to an all-time high and representing about 18% of the 165.8 million
shares outstanding.  

    The stock has seen a plethora of institutional buying and a fast appreciation in
price from November's low. In the past, much of the company's performance was based on
its success winning lawsuits against the major tobacco companies for product
infringement. Now, there are other catalysts expected to drive the stock within the next
few weeks. In the near future there is going to be a release of the Johns Hopkins Third
Party CRO results testing humans for its Thyroid treatment using Star Scientific's
Anatabloc Technology. Of greatest importance of course is if the Thyroid results are
positive, as this will be the first time an autoimmune disease has been put into
remission. If Star's Anatabloc Technology can treat or cure one autoimmune disease, in
this case "Hashimoto" Thyroiditis, then there is no reason to think it cannot help cure
other autoimmune diseases such as Diabetes, Rosacea and Alzheimer's.  

    Clearly this is not just a catalyst but also a ground-breaking event as the
possibilities of the technology are endless and can significantly advance the medical
industry against these aforementioned diseases. The Thyroid research has been done by
the Johns Hopkins University School of Medicine, one of the most preeminent medical
institutions in the world, under the lead of Paul Ladenson, Hopkins Chief
Endocrinologist. It is widely believed that Dr. Ladenson will use of Anatabloc in
Thyroid treatment and that Hopkins will continue to test this technology, and its
efficacy on at least two or three diseases other than Thyroid.  

    If the technology is a success, sales of Star's consumer product Anatabloc will rise
significantly and have immediate effects on the company's bottom line in the upcoming
quarters. With any company that is experimenting with new technology and treatments
there is some risk, however, the upside potential is tremendous considering that the
stock trades at $2.65. Most options are more expensive than picking up some shares of
STSI, which has the potential to revolutionize the industry.  

    About EmergingGrowth.com  

    By offering 100% original and unmatched content by the best financial reporters,
writers and bloggers in the business, EmergingGrowth.com is emerging as a leading
digital financial media portal. Its services provide users, subscribers and advertisers
with a variety of content and tools through a range of online, social media, mobile and
other mobile outlets.  

    Since its inception, EmergingGrowth.com has distinguished itself from other
financial media companies with its sly approach to reading between the lines in order to
locate that needle in the haystack. Sign up today to see what EmergingGrowth.com has to

    NEW: Feature your company on EmergingGrowth.com. Find out how by filling out our
form at http://emerginggrowth.com/recommend-a-company-to-feature-on-emerging-growth  


    All information contained herein as well as on the EmergingGrowth.com 
[http://emerginggrowth.com ] website is obtained from sources believed to be reliable
but not guaranteed to be accurate or all-inclusive. All material is for informational
purposes only, is only the opinion of EmergingGrowth.com and should not be construed as
an offer or solicitation to buy or sell securities. In addition, Please make sure you
read and understand the Terms of Use [http://emerginggrowth.com/terms-of-use ], Privacy
Policy and the Disclosure [http://emerginggrowth.com/disclosure ] posted on the
EmergingGrowth.com [http://emerginggrowth.com ] website. Always remember that investing
in securities such as the ones listed within are for high-risk tolerant individuals only
and not the general public. Whether you are an experienced investor or not, you should
always consult with a stockbroker, financial advisor, or similar before purchasing or
selling any securities viewed on any emails sent from EmergingGrowth.com
[http://emerginggrowth.com ] or its website.  

    Join our Linked in Group [http://www.linkedin.com/groups?gid=4650356&trk=hb_side_g ]
Like us on Facebook [http://www.facebook.com/pages/EmergingGrowthcom/474647062557938 ]  


CONTACT:  info@EmergingGrowth.com, +1-305-323-5687
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.